Linking Diagnostics to Therapeutics
A diagnostic that is accurate, confirmatory, and timely allows for the transition from the initial empiric treatment to a targeted therapy. At the moment of this transition, a number of events can occur that improve patient outcomes and reduce the burden on healthcare. Ineffective drug therapies can be replaced with effective therapies. Patients receiving appropriate treatment recover faster, lowering in-patient length of stay. Removal of MRSA negative patients from unnecessary isolation reduces the likelihood of experiencing preventable adverse events during hospitalization.1 Having a timely diagnostic that links to the appropriate therapy is the key to unlocking downstream benefits such as these. DxRx symbolizes the linking of diagnostics to therapeutics and the impact that is created. Through TEM-PCR™, Diatherix Laboratories is able to provide multiplex molecular diagnostics capable of DxRx.
In order to identify and share the impacts of DxRx, Diatherix actively participates in evidence based clinical outcome studies. The data from these studies illustrates how our diagnostic services have a far reaching impact for our clients and their patients. A bloodstream infection study by Huntsville Hospital in 2009 states that if Diatherix TEM-PCR™ results had been used in all test cases, therapy could have been optimized in 40% of cases, de-escalated in 28%, and stopped due to contamination in 21%.2 This study also found that on average, antimicrobial costs were reduced by 20% and ICU length of stay was reduced by 23%.2 In this case, when therapy was supported diagnostically rather than managed empirically, patient outcomes were improved, antimicrobial stewardship increased, and hospital costs were reduced.